Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer.
MetadataShow full item record
<h4>Background</h4>Epigenetic information can be used to identify clinically relevant genomic variants single nucleotide polymorphisms (SNPs) of functional importance in cancer development. Super-enhancers are cell-specific DNA elements, acting to determine tissue or cell identity and driving tumor progression. Although previous approaches have been tried to explain risk associated with SNPs in regulatory DNA elements, so far epigenetic readers such as bromodomain containing protein 4 (BRD4) and super-enhancers have not been used to annotate SNPs. In prostate cancer (PC), androgen receptor (AR) binding sites to chromatin have been used to inform functional annotations of SNPs.<h4>Results</h4>Here we establish criteria for enhancer mapping which are applicable to other diseases and traits to achieve the optimal tissue-specific enrichment of PC risk SNPs. We used stratified Q-Q plots and Fisher test to assess the differential enrichment of SNPs mapping to specific categories of enhancers. We find that BRD4 is the key discriminant of tissue-specific enhancers, showing that it is more powerful than AR binding information to capture PC specific risk loci, and can be used with similar effect in breast cancer (BC) and applied to other diseases such as schizophrenia.<h4>Conclusions</h4>This is the first study to evaluate the enrichment of epigenetic readers in genome-wide associations studies for SNPs within enhancers, and provides a powerful tool for enriching and prioritizing PC and BC genetic risk loci. Our study represents a proof of principle applicable to other diseases and traits that can be used to redefine molecular mechanisms of human phenotypic variation.
Version of record
Genetic Predisposition to Disease
Cell Cycle Proteins
Gene Expression Regulation, Neoplastic
Polymorphism, Single Nucleotide
Quantitative Trait Loci
Enhancer Elements, Genetic
Genome-Wide Association Study
License start date
BMC genomics, 2017, 18 (1), pp. 270 - ?
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Showing items related by title, author, creator and subject.
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Zhang, YD; Hurson, AN; Zhang, H; Choudhury, PP; Easton, DF; Milne, RL; Simard, J; Hall, P; Michailidou, K; Dennis, J; Schmidt, MK; Chang-Claude, J; Gharahkhani, P; Whiteman, D; Campbell, PT; Hoffmeister, M; Jenkins, M; Peters, U; Hsu, L; Gruber, SB; Casey, G; Schmit, SL; O'Mara, TA; Spurdle, AB; Thompson, DJ; Tomlinson, I; De Vivo, I; Landi, MT; Law, MH; Iles, MM; Demenais, F; Kumar, R; MacGregor, S; Bishop, DT; Ward, SV; Bondy, ML; Houlston, R; Wiencke, JK; Melin, B; Barnholtz-Sloan, J; Kinnersley, B; Wrensch, MR; Amos, CI; Hung, RJ; Brennan, P; McKay, J; Caporaso, NE; Berndt, SI; Birmann, BM; Camp, NJ; Kraft, P; Rothman, N; Slager, SL; Berchuck, A; Pharoah, PDP; Sellers, TA; Gayther, SA; Pearce, CL; Goode, EL; Schildkraut, JM; Moysich, KB; Amundadottir, LT; Jacobs, EJ; Klein, AP; Petersen, GM; Risch, HA; Stolzenberg-Solomon, RZ; Wolpin, BM; Li, D; Eeles, RA; Haiman, CA; Kote-Jarai, Z; Schumacher, FR; Al Olama, AA; Purdue, MP; Scelo, G; Dalgaard, MD; Greene, MH; Grotmol, T; Kanetsky, PA; McGlynn, KA; Nathanson, KL; Turnbull, C; Wiklund, F; Breast Cancer Association Consortium (BCAC); Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON); Colon Cancer Family Registry (CCFR); Transdisciplinary Studies of Genetic Variation in Colorectal Cancer (CORECT); Endometrial Cancer Association Consortium (ECAC); Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO); Melanoma Genetics Consortium (GenoMEL); Glioma International Case-Control Study (GICC); International Lung Cancer Consortium (ILCCO); Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium; International Consortium of Investigators Working on Non-Hodgkin’s Lymphoma Epidemiologic Studies (InterLymph); Ovarian Cancer Association Consortium (OCAC); Oral Cancer GWAS; Pancreatic Cancer Case-Control Consortium (PanC4); Pancreatic Cancer Cohort Consortium (PanScan); Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL); Renal Cancer GWAS; Testicular Cancer Consortium (TECAC); Chanock, SJ; Chatterjee, N; Garcia-Closas, M (2020-07-03)Genome-wide association studies (GWAS) have led to the identification of hundreds of susceptibility loci across cancers, but the impact of further studies remains uncertain. Here we analyse summary-level data from GWAS of ...
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Scott, RA; Freitag, DF; Li, L; Chu, AY; Surendran, P; Young, R; Grarup, N; Stancáková, A; Chen, Y; Varga, TV; Yaghootkar, H; Luan, J; Zhao, JH; Willems, SM; Wessel, J; Wang, S; Maruthur, N; Michailidou, K; Pirie, A; van der Lee, SJ; Gillson, C; Al Olama, AA; Amouyel, P; Arriola, L; Arveiler, D; Aviles-Olmos, I; Balkau, B; Barricarte, A; Barroso, I; Garcia, SB; Bis, JC; Blankenberg, S; Boehnke, M; Boeing, H; Boerwinkle, E; Borecki, IB; Bork-Jensen, J; Bowden, S; Caldas, C; Caslake, M; CVD50 consortium; Cupples, LA; Cruchaga, C; Czajkowski, J; den Hoed, M; Dunn, JA; Earl, HM; Ehret, GB; Ferrannini, E; Ferrieres, J; Foltynie, T; Ford, I; Forouhi, NG; Gianfagna, F; Gonzalez, C; Grioni, S; Hiller, L; Jansson, J-H; Jørgensen, ME; Jukema, JW; Kaaks, R; Kee, F; Kerrison, ND; Key, TJ; Kontto, J; Kote-Jarai, Z; Kraja, AT; Kuulasmaa, K; Kuusisto, J; Linneberg, A; Liu, C; Marenne, G; Mohlke, KL; Morris, AP; Muir, K; Müller-Nurasyid, M; Munroe, PB; Navarro, C; Nielsen, SF; Nilsson, PM; Nordestgaard, BG; Packard, CJ; Palli, D; Panico, S; Peloso, GM; Perola, M; Peters, A; Poole, CJ; Quirós, JR; Rolandsson, O; Sacerdote, C; Salomaa, V; Sánchez, M-J; Sattar, N; Sharp, SJ; Sims, R; Slimani, N; Smith, JA; Thompson, DJ; Trompet, S; Tumino, R; van der A, DL; van der Schouw, YT; Virtamo, J; Walker, M; Walter, K; GERAD_EC Consortium; Neurology Working Group of the Cohorts for Heart; Aging Research in Genomic Epidemiology (CHARGE); Alzheimer’s Disease Genetics Consortium; Pancreatic Cancer Cohort Consortium; European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD); EPIC-InterAct; Abraham, JE; Amundadottir, LT; Aponte, JL; Butterworth, AS; Dupuis, J; Easton, DF; Eeles, RA; Erdmann, J; Franks, PW; Frayling, TM; Hansen, T; Howson, JMM; Jørgensen, T; Kooner, J; Laakso, M; Langenberg, C; McCarthy, MI; Pankow, JS; Pedersen, O; Riboli, E; Rotter, JI; Saleheen, D; Samani, NJ; Schunkert, H; Vollenweider, P; O'Rahilly, S; CHARGE consortium; CHD Exome+ Consortium; CARDIOGRAM Exome Consortium; Deloukas, P; Danesh, J; Goodarzi, MO; Kathiresan, S; Meigs, JB; Ehm, MG; Wareham, NJ; Waterworth, DM (2016-06)Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to guide development of antidiabetic ...
An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. Wu, L; Yang, Y; Guo, X; Shu, X-O; Cai, Q; Shu, X; Li, B; Tao, R; Wu, C; Nikas, JB; Sun, Y; Zhu, J; Roobol, MJ; Giles, GG; Brenner, H; John, EM; Clements, J; Grindedal, EM; Park, JY; Stanford, JL; Kote-Jarai, Z; Haiman, CA; Eeles, RA; Zheng, W; Long, J; PRACTICAL consortium; CRUK Consortium; BPC3 Consortium; CAPS Consortium; PEGASUS Consortium (2020-08-06)It remains elusive whether some of the associations identified in genome-wide association studies of prostate cancer (PrCa) may be due to regulatory effects of genetic variants on CpG sites, which may further influence ...